A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
Mahmoud A Khaimi Dean McGee Eye Institute, Oklahoma City, OK, USA Background: While loteprednol etabonate (LE) suspension 0.5% is approved for the treatment of postoperative ocular inflammation, there have been no reported studies of its use in glaucoma patients undergoing canaloplasty.Methods: Th...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2018
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/788604a75ed14273a9b9762b4b64c71f |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|